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ER/K linked GPCR-G protein fusions 
systematically modulate second 
messenger response in cells
Rabia U. Malik1, Matthew Dysthe1, Michael Ritt1, Roger K. Sunahara  2 &  
Sivaraj Sivaramakrishnan1
FRET and BRET approaches are well established for detecting ligand induced GPCR-G protein 
interactions in cells. Currently, FRET/BRET assays rely on co-expression of GPCR and G protein, and 
hence depend on the stoichiometry and expression levels of the donor and acceptor probes. On the 
other hand, GPCR-G protein fusions have been used extensively to understand the selectivity of GPCR 
signaling pathways. However, the signaling properties of fusion proteins are not consistent across 
GPCRs. In this study, we describe and characterize novel sensors based on the Systematic Protein 
Affinity Strength Modulation (SPASM) technique. Sensors consist of a GPCR and G protein tethered by 
an ER/K linker flanked by FRET probes. SPASM sensors are tested for the β2-, α1-, and α2- adrenergic 
receptors, and adenosine type 1 receptor (A1R), tethered to Gαs-XL, Gαi2, or Gαq subunits. Agonist 
stimulation of β2-AR and α2-AR increases FRET signal comparable to co-expressed FRET/BRET sensors. 
SPASM sensors also retain signaling through the endogenous G protein milieu. Importantly, ER/K linker 
length systematically tunes the GPCR-G protein interaction, with consequent modulation of second 
messenger signaling for cognate interactions. SPASM GPCR sensors serve the dual purpose of detecting 
agonist-induced changes in GPCR-G protein interactions, and linking these changes to downstream 
signaling.
G protein coupled receptors relay detection of stimuli such as photons, neurotransmitters, hormones, or drugs 
from the extracellular milieu to the intracellular environment by binding and activating one or more functionally 
distinct heterotrimeric G proteins1. Coupling between an active GPCR and G proteins stimulates accumulation 
of second messengers such as cyclic AMP, calcium/potassium ions, and inositol phosphate1. Efforts to monitor 
and understand the link between GPCR-G protein interactions and downstream second messenger response 
are complicated by the range of cellular factors that influence GPCR signaling including the relative localization 
and abundance (concentration) of GPCR and G proteins, regulatory proteins such as Regulators of G protein 
Signaling (RGS), G protein kinases (GRKs), and non-G protein effectors such as β-arrestins2.
Current approaches to visualize GPCR-G protein interaction in cells involve probing the interaction between 
individually expressed fluorescent or luminescent protein fusions using fluorescence/bioluminescence resonance 
energy transfer (FRET/BRET)3–7. Therefore, insights into the GPCR-G protein interaction gained from these 
studies are limited by their dependence on the relative concentration and co-localization of individually expressed 
GPCR and G protein. Alternatively, direct GPCR-G protein fusions generated by tethering the N-terminus of the 
Gα to the GPCR’s C-tail either directly or with a short linker in between have been used to study the influence of 
tethering different G protein subunits on G protein activation and second messenger signaling8, 9. Such fusions 
have not been used to monitor the GPCR-G protein interaction using resonance energy transfer approaches6. A 
limitation of direct fusions is that GPCRs with short C-tails do not efficiently signal to the tethered G protein10–13.
Here, we combine the strengths of FRET and fusion proteins by leveraging the Systematic Protein Affinity 
Strength Modulation (SPASM) approach14, 15. GPCR SPASM sensors involve expression of a single polypeptide 
encoding a GPCR tethered to a G protein via an ER/K α-helix/linker that is flanked by a pair of FRET probes 
(mCitrine (FRET acceptor) and mCerulean (FRET donor)) (Fig. 1a). Unstructured (Gly-Ser-Gly)4 linkers are 
inserted in between each component to provide rotational flexibility (Fig. 1a). Similar to GPCR fusions, GPCR 
SPASM sensors enable control over GPCR-G protein stoichiometry and co-localization. ER/K linkers with 
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end-to-end distance of 10–30 nm (measured along the α-helical backbone) are designed to provide adequate sep-
aration between the GPCR (~3 nm) and the G protein (~5 nm)14, 16. Increasing ER/K linker length from 10–30 nm 
has been shown to systematically decrease the effective concentration of the protein-protein interaction from 
10 μM to 100 nM14, 15, 17, 18. We have previously reported on SPASM sensors involving fusions of GPCRs with 
C-terminal peptides of the Gα subunits19–21. Here, we describe SPASM GPCR sensors with the entire Gα subunit 
that can bridge the gap between the GPCR-G protein interaction and downstream signaling10–13.
In this proof-of-concept study, SPASM sensors are made for four GPCRs with varying C-tail lengths (8–87 
amino acids). The β2-adrenergic receptor (β2-AR), α2-adrenergic receptor (α2-AR), α1-adrenergic receptor 
Figure 1. GPCR-G protein fusion sensors are intact and functional. (a) Schematic of the GPCR-G protein 
sensor design. Protein domains are separated by (GSG)4 linkers to ensure rotational freedom. Control (–) 
sensors do not contain a Gα subunit. (b) Sensors localize to the plasma membrane in live HEK293T cells 
as shown in representative images. (c) Western blot of membranes expressing HA-β2-AR-Gαs probed with 
anti-HA antibody. A distinct 150 kDa band indicates intact sensor expression. (d) Membranes expressing HA-
β2-AR-Gαx sensors were subjected to HA-affinity purification and probed with anti-Gβ antibody. Equivalent 
amount of sensor is loaded per lane as assessed by mCitrine fluorescence. Gβ associates with the Gαs, Gαi, 
or Gαq subunit. (e) cAMP production in the presence or absence of inverse agonist (100 μM metoprolol) for 
β2-AR tethered with or without Gs. Data are derived from at least three independent experiments, with at least 
three replicates per condition. Data are represented as % no-G protein control (–) (mean ± S.E.M Student’s t-test 
was performed to evaluate significance **p ≤ 0.01 and ***p ≤ 0.001).
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(α1-AR), and adenosine type 1 receptor (A1R) are each tethered to functionally distinct Gα subunits (Gαs-XL, 
Gαi2, and Gαq). Consistent with literature reports of co-expressed GPCR-G protein sensors3, 5, we find SPASM 
sensors with cognate GPCR-G protein pairs show enhanced interaction following agonist stimulation as indi-
cated by a gain in FRET signal. Varying ER/K linker length from 10 nm to 30 nm systematically tunes the basal 
interaction between tethered GPCR-G protein pairs. However it only modulates second messenger response from 
select GPCR-G protein pairs over and above endogenous levels. Together, these features of the SPASM GPCR-G 
protein sensors facilitate both the detection of GPCR-G protein interactions in cells and establish their link to 
downstream signaling pathways.
Results
Integrity of GPCR-G protein fusions. The GPCR and Gα subunit were expressed as a single polypeptide 
fusion with a SPASM module between them (Fig. 1a). All individual protein elements are separated by (Gly-
Ser-Gly)4 linkers to provide rotational flexibility (Fig. 1a). The SPASM module provides 1:1 stoichiometry of 
GPCR-Gα expression and consists of an ER/K α-helical linker flanked by a FRET pair (mCerulean/mCitrine)14. 
FRET probes enable monitoring of cellular expression and sensor integrity. Fusions lacking a G protein (–) served 
as controls to assess background signaling through endogenous G proteins. Together, these sensor properties 
facilitate pairwise comparison across fusions at matched cellular expression levels (see Methods). GPCR-G pro-
tein fusions were initially generated for the prototypical β2 adrenergic receptor (β2-AR). Fusions are expressed 
primarily ( > 80%; Supplementary Fig. 1) at the plasma membrane of HEK293T cells (Fig. 1b), are intact as 
assessed by immuno-blotting membrane preparations (Fig. 1c), and bind Gβγ subunits to equal extents (Fig. 1d). 
Fusions retain the ability to bind agonist, as witnessed by competitive displacement of [3H]DHA by isoproter-
enol binding to the receptor in the β2-AR-Gs fusions (Ki ~ 98 nM) (Supplementary Fig. 2). The calculated Ki is 
similar to previous reports of low affinity binding of isoproterenol in the absence of a high molar ratio of β2-AR 
to Gs (β2-AR – 1.4 pmol/mg; Gs ~ 100 pmol/mg)22. Hence, the ER/K linker does not promote ternary complex 
formation within the SPASM sensor. Consistent with the known basal activity of this GPCR, over-expression of 
β2-AR (1–2 pmol/mg total protein) elevates basal cAMP levels relative to the untransfected (UN) cells (Fig. 1e)23. 
Treatment with the inverse agonist metoprolol (Meto) significantly attenuates the enhanced cAMP levels, attest-
ing to the role of exogenously expressed β2-AR (Fig. 1e). The functionality of Gs in the β2-AR-Gs fusion protein 
is witnessed by the ~5-fold increase in basal cAMP levels as compared to sensors expressing β2-AR alone (–) 
(Fig. 1e). Together, these measurements support the functional integrity of the β2-AR-Gs SPASM sensors in cells.
Agonists modulate fusion interaction and downstream response. In agreement with previous 
β2-AR-Gs fusions22, 24, tethering β2-AR to Gs with a 10 nm ER/K linker enhances both efficacy (Fig. 2a) and 
potency (β2-AR-Gs EC50 = 0.09 ± 0.05 nM; β2-AR EC50 = 0.44 ± 0.3 nM; Fig. 2b) of the isoproterenol induced 
cAMP levels compared to over-expression of β2-AR alone (–). Likewise, epinephrine treatment results in a greater 
loss in cAMP signaling for ER/K linked α2-AR-Gi compared to α2-AR alone (–) (Fig. 2c). To test if agonist stim-
ulation enhances interaction between the cognate GPCR-G protein pair, changes in FRET ratio were examined. 
The SPASM module is designed to maintain low FRET levels in the absence of an interaction between the GPCR 
and G protein (dissociated state; Fig. 3a)14. Interaction between the GPCR and G protein (associated state; Fig. 3a) 
should bring the FRET donor and acceptor in closer proximity, leading to higher FRET levels. In accordance 
with previous studies using co-expressed GPCR and G protein FRET/BRET pair fusions, treatment with agonist 
Figure 2. Agonist enhances downstream second messenger response via the fused G protein. (a) cAMP 
production in the presence of (a) saturating (100 μM) or (b) varying concentration of isoproterenol for β2-AR 
tethered with or without (–) Gs. (b) Data are represented as percent maximum cAMP levels for 100 μM 
isoproterenol treatment of β2-AR fusions tethered with or without (–) Gs. (c) Percent inhibition of 1 μM 
forskolin induced cAMP production for α2-AR fusions with or without Gi treated with 100 μM epinephrine. 
Data are derived from at least three independent experiments, with at least three replicates per condition 
(mean ± S.E.M. Student’s t-test was performed to evaluate significance *p ≤ 0.05; **p ≤ 0.01).
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(100 μM isoproterenol) results in a gain in FRET for the cognate β2-AR-Gs pairing3, 4, but not for non-cognate 
Gi, Gq, or fusions lacking a G protein (–) in live cells (Fig. 3b). Likewise, for the Gi coupled receptor, α2-AR, 
stimulation with 100 μM epinephrine induced a gain in FRET for Gi4, 5, but not Gs or Gq (Fig. 3c). ΔFRET for 
β2-AR-Gs = 0.006 ± 0.001 and α2-A-Gi = 0.01 ± 0.002 are small but statistically significant. These changes are 
comparable to previously reported measurements using co-expressed sensors of β2-AR-Gs (ΔBRET ~0.025) 
and α2-AR-Gi (ΔFRET ~0.022)3–5, 25. Agonist induced β2-AR interaction with Gs is reversible, as isoprotenerol 
Figure 3. Agonist modulates cognate GPCR-Gx fusion interactions. (a) Schematic of the GPCR-G protein 
fusions linked with the 10 nm ER/K linker in the associated (high FRET) and dissociated (low FRET) states in 
live cells. (b,c) Change in FRET (ΔFRET) for indicated GPCR-Gx fusions following agonist treatment in live 
cells ((b) 100 μM isoproterenol (ISO) and (c) 1 mM epinephrine (EPI)). GPCRs are colored by their cognate 
G proteins; red and green indicate Gs (β2-AR) and Gi (α2-AR) coupled receptors respectively. (d) For ligand 
wash out experiments, change in FRET (ΔFRET) for cells expressing β2-AR-Gs fusion was assessed in the 
presence or absence of 100 μM ISO. Following addition of ISO, cells were subsequently washed with wash buffer 
supplemented with (filled) or without (open) 100 μM ISO. (e) Change in FRET (ΔFRET) for cells expressing β2-
AR-Gs fusion treated with 100 μM ISO for 1, 5, or 10 minutes. (f) Change in FRET (ΔFRET) for cells expressing 
β2-AR-Gs fusion treated with varying concentration of ISO. (g) Change in FRET (ΔFRET) for cells expressing 
β2-AR-Gs fusion treated with 100 μM of β2-AR ligands (full agonist ISO, partial agonist salbutamol (SAL), and 
inverse agonist metoprolol (MET)). Data are derived from at least three independent experiments, with at least 
three replicates per condition (mean ± S.E.M. Student’s t-test was performed to evaluate significance between 
ligand treated and untreated conditions, with *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001. One-way 
ANOVA with a Tukey’s post-test was performed to evaluate significance across multiple conditions, with 
##p ≤ 0.01, ####p ≤ 0.0001).
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washout returned FRET ratios to basal levels (ΔFRET −0.001 ± −0.002; Fig. 3d (open bar)). Consistent with 
internalization of β2-AR in HEK293 cells26, gain in FRET signal between β2-AR and Gs persisted up to 5 minutes 
and decreased following prolonged stimulation (10 minutes) with isoproterenol (Fig. 3e). Agonist stimulation 
led to a concentration-dependent gain in FRET between β2-AR-Gs fusion (EC50 = 39.69 nM; Fig. 3f), which 
paralleled the rise in cAMP production (EC50 = 0.09 nM; Fig. 2b). Compared with full agonist isoproterenol, at 
saturating concentrations (100 μM) the high affinity partial agonist salbutamol resulted in a ~63% decrease in 
ΔFRET for β2-AR-Gs fusion (Fig. 3g). Interestingly, metoprolol, an inverse agonist, partly suppresses β2-AR-Gs 
cAMP production (Fig. 1e), and displays a small but statistically significant gain in FRET (Fig. 3g). These find-
ings suggest that metoprolol weakly facilitates an interaction between β2-AR and Gs without resulting in robust 
cAMP production. Together, these data suggest that the ΔFRET assay reports on the ligand-dependent change in 
GPCR-G protein interaction but not necessarily the activity state of the receptor or G protein.
Fusions interact with endogenous G proteins. One concern with fusions is that the addition of the 
SPASM module at the C-tail of the GPCR may cause steric hindrance between GPCR interactions with the endog-
enous signaling machinery. The ER/K linked fusions are designed to spatially separate the GPCR and G protein in 
the absence of an interaction, and should therefore freely permit interactions with non-tethered G proteins14, 27. 
To test the ability of the ER/K linked fusions to interact with non-tethered G proteins in the cellular milieu, 
we focused on β2-AR and α1-AR interactions with Gs and Gq, as they influence distinct second messengers 
(cAMP and IP1) and facilitate interpretation of downstream responses. First, an unlabeled (dark) Gα subunit 
was increasingly co-expressed relative to the ER/K linked fusions, and the FRET ratios were determined for equal 
levels of expression of the ER/K linked fusion (Fig. 4a). Elevated expression of Gs or Gq, relative to β2-AR-Gs or 
α1-AR-Gq sensors, respectively, systematically decreased FRET ratios attesting to interactions between cellular 
Gs or Gq and the GPCR in the ER/K linked fusions (Fig. 4b,c). Likewise, tethering the cognate G protein (Gs 
and Gq, respectively, for β2-AR and α1-AR) increases second messenger signaling through the cognate pathway 
(cAMP and IP1, respectively, for β2-AR and α1-AR), whereas, tethering to the non-cognate G protein (Gq and 
Gs, respectively, for β2-AR and α1-AR) does not suppress signaling through endogenous G proteins (Fig. 4d,e 
– no significant difference between sensors without G protein compared to those with non-cognate G protein). 
Together, these measurements demonstrate that while the ER/K linked G protein does interact with the GPCR, it 
does not measurably perturb interactions with endogenous components.
Figure 4. Fusions modulate GPCR-G protein signaling relative to the endogenous cellular environment. 
(a) Schematic of competitive binding of un-tethered Gx (‘dark Gx’) to GPCR-Gx fusions. (b,c) FRET Ratios 
(525 nm/475 nm) for cells expressing GPCR-Gx fusion and cognate Gx after transient co-transfection with 
different concentrations of dark Gx DNA (0, 100, 300, and 1000 ng well−1). GPCR-Gx fusion DNA (2–4 μg 
well−1) was optimized to maintain equivalent expression across conditions. FRET Ratios for cells co-expressing 
(b) β2-AR-Gs fusions with unlabeled dark Gs (red) or (c) α1-AR-Gq fusions with dark Gq (blue). (d) Basal 
cAMP and (e) IP1 levels for cells expressing (d) β2-AR and (e) α1-AR tethered to Gs, Gq, or no G protein (–). 
(b–e) Data are derived from at least three independent experiments, with at least three replicates per condition 
(mean ± S.E.M. Student’s t-test was performed to evaluate significance with *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; 
****p ≤ 0.0001).
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ER/K linker length modulates second messenger signaling of cognate GPCR-G protein fusions. 
Previous studies show that increasing ER/K linker length from 10 to 30 nm decreases the effective concentration 
of the tethered proteins from 10 μM to 100 nM14. FRET ratios are sensitive to the distance between and concen-
tration of acceptor and donor molecules6. As expected, FRET ratio measurements for matched sensor expression 
demonstrate that increasing ER/K linker length from 10 to 30 nm, systematically decreased basal FRET ratios for 
a range of both cognate and non-cognate GPCR-G protein interactions (Figs 5 and 6; FRET ratios are depicted by 
open black circles; GPCR color indicates its cognate G protein). To test whether modulating the GPCR-G protein 
interaction within the ER/K linked fusion influences downstream signaling, the second messenger corresponding 
to the tethered G protein was measured under matched protein expression levels (Figs 5 and 6; Filled circles with 
colors corresponding to the second messenger; red – cAMP; green – suppression of forskolin-stimulated cAMP; 
blue – IP1). In correlation with the systematic changes in the relative GPCR-Gx fusions interaction (FRET ratios), 
significant modulation of second messenger levels was observed only for cognate GPCR-G protein fusions (Figs 5 
and 6). Specifically, tethering β2-AR (Gs coupled receptor) to Gs modulates cAMP (Fig. 5b), whereas tethering 
α1-AR (Gq coupled receptor) to Gq modulates IPx (Fig. 5d). In contrast, tethering β2-AR to Gq or α1-AR to Gs 
modulates the GPCR-Gx interaction (FRET ratio) but not IP1 or cAMP levels respectively (Fig. 5c,e). Tethering 
A1R (Gi coupled receptor) to Gi suppresses forskolin-stimulated cAMP levels, whereas tethering to Gs does not 
enhance cAMP (Fig. 6b,c). Interestingly, α2-AR, which has been shown to couple to both Gs and Gi28, shows 
both enhanced cAMP upon tethering to Gs and suppression of forskolin-stimulated cAMP upon tethering to 
Gi (Fig. 6d,e), unlike previously reported α2-AR fusions11. Together, these measurements support the ability of 
ER/K linked cognate GPCR-G protein fusions to successfully modulate signaling relative to endogenous levels.
Discussion
In this study, we demonstrate the utility of ER/K-linked fusion sensors15 in examining the correlation between 
GPCR-G protein interaction and downstream signaling. Modulating the GPCR-G protein interaction using the 
ER/K linker systematically varies downstream signaling from cognate GPCR-G protein interactions (Figs 5b,d 
and 6b,d). In contrast, GPCRs tethered to non-cognate G protein do not show detectable downstream response 
for the non-cognate pathway (Figs 5c,e and 6c). Instead, non-cognate GPCR-G protein pairings retain signaling 
through the endogenous pathways (Fig. 4d,e). Likewise, increasing the concentration of exogenously expressed 
unlabeled Gα subunits diminishes interactions within ER/K linked fusions (Fig. 4b,c). Hence, our data suggest 
that rather than enforce GPCR-G protein coupling9, 13, 22 or sterically hinder interactions with endogenous G 
proteins10, 11, 13 the SPASM sensors can systematically modulate signaling relative to endogenous levels.
In contrast to previous GPCR-G protein fusions that use a short unstructured linker9–11, 13, 22, 29, in the absence 
of an interaction, the structured ER/K linker provides a significant spatial separation between the GPCR and the 
G protein fused to its ends. The ER/K linker has been previously characterized to exist primarily in an extended 
α-helical conformation, with end-to-end distances of ~7 to ~22 nm for 10 to 30 nm lengths along the α-helical back-
bone27. ER/K linkers are designed to modulate the effective concentration of the intra-molecular interaction14, 15, 
where the same linker length provides matched effective concentration across different GPCR-G protein pair-
ings. However, given the localization of both GPCRs and G proteins on the plasma membrane, and the potential 
segregation of GPCRs into membrane micro-domains30, the measurements from any FRET/BRET based assay 
in live cells will have contributions from both intra-molecular interactions and those induced by the proximity 
of sensors on the plasma membrane31. Hence, measurements in each figure panel were performed with matched 
sensor expression, as determined by mCitrine fluorescence per unit cell density (see Methods). Despite potential 
limitations, the FRET ratio does decrease systematically with increasing ER/K linker length for all of the GPCR-G 
protein combinations tested suggesting that the ER/K linker alters the proximity and interaction between GPCR 
and G protein (Figs 5 and 6).
Unlike current FRET/BRET sensors that rely on the co-expression of labeled GPCR and G protein subunits3–7, 32, 33, 
the SPASM sensors enable the expression of a single polypeptide that provides 1:1 stoichiometry between the 
exogenously expressed GPCR and G protein. The specificity of the FRET response is validated using the prototyp-
ical receptor β2-AR, where agonist stimulation enhances interaction with its cognate Gs protein, with a parallel 
increase in downstream second messenger signaling (Figs 2b and 3f). Agonist stimulation provides changes in 
FRET comparable to those previously reported using co-expressed FRET/BRET pairs3–5 (Fig. 3b,c). The enhanced 
FRET is dose-dependent, reversible, and diminishes following prolonged treatment with agonist. (Fig. 3d–f). 
These observations establish the use of the ER/K-linked fusions to monitor ligand-induced changes in GPCR-G 
protein interactions in cells.
One of the advantages of ER/K-linked fusions is the ability to directly compare and contrast interaction and 
downstream signaling from distinct ligand-GPCR-G protein pairings. Our preliminary findings suggest two sig-
nificant limitations in the interpretation of FRET-based measurements of GPCR-G protein interactions in cells. 
First, the ligand-induced changes in interaction do not necessarily correlate with the strength of downstream sig-
naling. While the full agonist isoprotenerol elicits a larger FRET response than the partial agonist salbutamol, the 
inverse agonist metoprolol shows a small but significant increase in FRET signal (Fig. 3g). This paradoxical obser-
vation is consistent with previous reports of inactive GPCR-G protein complexes in cells7, and suggests that meto-
prolol facilitates a β2-AR-Gs interaction without G protein activation (Figs 1e and 3g). Second, ligand potency as 
measured using FRET is significantly lower than the potency of the downstream response. Isoprotenerol has an 
EC50 of 39.7 nM for FRET compared to 0.1 nM for cAMP (Figs 2b and 3f). Isoproterenol affinity for the β2-AR-Gs 
sensor was measured independently to be 98 nM (Supplementary Fig. 2). To gain insight into factors contributing 
to the discrepancy between the ligand potencies (FRET vs. downstream signaling), ligand efficacy (τ) was evalu-
ated (see Methods)34. The fractional occupancy of the receptor for generating half maximal response is 3.9% (1/τ, 
Supplementary Table 5), indicating that only a small population of isoproterenol bound β2-AR-Gs is needed to 
generate maximal cAMP production. In contrast, the FRET response of SPASM sensors is expected to be linearly 
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Figure 5. ER/K linker length specifically modulates basal β2-AR-Gs and α1-AR-Gq downstream response in 
live cells. (a) Schematic of the GPCR-G protein fusions. Color represents cognate GPCR-G protein pair and 
corresponding downstream response (red: β2-AR, Gs, and cAMP levels; blue: α1-AR, Gq, and IP1 signal). (b–e) 
Fusion type is indicated on the top left. FRET Ratios (525 nm/475 nm; open black circles, right y-axis) and basal 
(ligand-free) downstream response (filled colored circles, left y-axis) are compared to ER/K linker length (nm). 
(b) cAMP levels or (c) IP1 signal for β2-AR tethered to cognate Gs or non-cognate Gq respectively. (d) IP1 signal 
for cognate α1-AR-Gq fusions. (e) cAMP levels for α1-AR tethered to non-cognate Gs. (b–e) One-way ANOVA 
with a Tukey’s post-test was performed for FRET measurements (black) and downstream response (colored). 
Data are derived from at least three independent experiments, with at least three replicates per condition 
(mean ± S.E.M. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001). For additional statistical analysis see 
Supplementary Table 3.
www.nature.com/scientificreports/
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Figure 6. ER/K linker length tunes basal GPCR-Gi protein downstream response in live cells. (a) Schematic of 
the GPCR-G protein fusions. Color represents cognate GPCR-G protein pair and corresponding downstream 
response (red: α2-AR, Gs, and cAMP levels; green: A1R, α2-AR, Gi, and cAMP inhibition). (b–e) Fusion type is 
indicated on the top left. FRET Ratios (525 nm/475 nm; open black circles, right y-axis) and basal (ligand-free) 
downstream response (filled colored circles, left y-axis) are compared to ER/K linker length (nm). (b) Percent 
inhibition of 1 μM forskolin induced cAMP production for canonical Gi coupled adenosine type 1 receptor 
(A1R). (c) Basal cAMP levels for A1R-Gs fusions. (d) % cAMP inhibition for Gi fusions and (e) cAMP levels 
for Gs fusions to α2-AR, a promiscuous Gs/Gi coupled receptor28. (b,d) Representative experiment with at 
least three replicates per condition. (c,e) Data are derived from at least three independent experiments, with at 
least three replicates per condition. (b–e) One-way ANOVA with a Tukey’s post-test was performed for FRET 
measurements (black) and downstream response (colored). Data are represented as mean ± S.E.M. *p ≤ 0.05; 
**p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001). For additional statistical analysis see Supplementary Table 4.
www.nature.com/scientificreports/
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proportional to the fraction of G proteins interacting with the GPCR at equilibrium14. Hence, the proportion of 
GPCRs interacting with G protein will be limited, in part, by the ligand binding affinity. Accordingly, the EC50 of 
the FRET measurement is similar to the isoproterenol binding affinity calculated using the radio-ligand binding 
assay (Fig. 3f and Supplementary Fig. 2). Taken together, comparison of dose response curves for ligand binding, 
GPCR-G protein FRET, and cAMP response, for the same sensor construct reveal that dose-response curves of 
FRET are limited by ligand binding, and therefore cannot reliably report on efficacy of downstream signaling. 
While our studies clearly demonstrate limitations in inferring activity state of the GPCR from FRET, they do 
provide additional insight into the GPCR-G protein interaction especially when combined with complementary 
approaches such as radio-ligand binding and second messenger response.
GPCR-G protein SPASM sensors provide a novel approach to probe the link between GPCR-G protein inter-
action and downstream signaling responses. We have previously reported on ER/K linked fusions of GPCR and 
peptides derived from the Gα C-terminus19–21. Unlike the GPCR-G protein sensors, the GPCR-Gα C-terminus 
peptide sensors show a direct correlation between FRET and downstream signaling19, 21. The Gα C-terminus 
is a well-characterized component of the GPCR-G protein interface that inserts itself into the cytosolic groove 
of the activated GPCR16, 35, 36. Further, strong binding of the Gα C-terminus with the GPCR facilitates G pro-
tein activation, suggesting that GPCR interactions with the Gα C-terminus may provide a measure of ligand 
efficacy37, 38. We have previously reported that while metoprolol shows a paradoxical increase in a β2-AR-Gs 
interaction, it decreases the β2-AR interaction with Gαs C-terminus while enhancing the interaction with the 
Gαi C-terminus, with a corresponding increase in downstream Gi signaling21. Hence, the GPCR-G protein and 
GPCR-Gα C-terminus sensors provide complementary tools for dissecting the interaction and signaling state of 
the GPCR.
Methods
Reagents and buffers. Fibronectin, guanosine 5′-diphosphate sodium salt (GDP), 3-isobutyl-1-methylx-
anthine (IBMX), (−)-isoproterenol (+)- bitartrate salt, forskolin, and metoprolol tartarate were purchased from 
Sigma-Aldrich. Salbutamol hemisulfate was acquired from Tocris. n-dodecyl-β-D-maltopyranoside, Anagrade 
(DDM) was bought from Anatrace. Anti-Gβ antibody (SC378) and anti-HA antibody (MMS-101p) were pur-
chased from Santa Cruz Biotechnology and Covance respectively. cDNAs for α1A-AR isoform 3 (Homo sapiens), 
and α2A-AR (Sus scrofa) were kind gifts from Dr. Richard Neubig. cDNAs for human β2-AR, long splice variant 
of Gαs, Gαi2 isoform 1, and Gαq were purchased from GE (Open Biosystems). Human A1R was acquired from 
DNASU Plasmid Repository. DNA transfection reagents X-tremeGENE HP and Mirus-LT DNA were acquired 
from Roche and Mirus respectively. Buffer A is 20 mM HEPES, 5 mM KCl, 145 mM NaCl, 2 mM CaCl2, 1 mM 
MgCl2, 0.2% dextrose (w/v), 1.5 μg mL−1 aprotinin and 1.5 μg mL−1 leupeptin at pH 7.45. Buffer B is 20 mM 
HEPES, 0.5 mM EDTA, 5 mM MgCl2, 0.1 mM DTT, 10 μM GDP, 1.5 μg mL−1 aprotinin, 1.5 μg mL−1 leupeptin 
and 50 μg mL−1 phenylmethanesulfonyl fluoride (PMSF) at pH 7.4. Buffer C is 20 mM HEPES, 0.5% decaethyl-
ene glycol monododecyl ether (C12E10), 100 mM NaCl, 1 mM MgCl2 10 μM GDP, 5.5 mM β-mercaptoethanol, 
10 μg mL−1 PMSF at pH 8.0. Buffer D is Phosphate Buffered Saline (PBS pH 7.4; GibcoTM), 800 μM ascorbic acid, 
and 0.2% dextrose (w/v).
Molecular cloning. PCR products for α1A-AR (isoform 3), β2-AR, A1R, long splice variant of Gαs, Gαi2, 
and Gαq were obtained from human cDNA. For mammalian HEK293 expression, all GPCR and Gα con-
structs were cloned into a PCDNA5/FRT vector. A modular scheme was designed for cloning of GPCR sen-
sors. Each GPCR-G protein sensor contained from N- to C-terminus: a full length GPCR, mCitrine (FRET 
acceptor), 10, 20 or 30 nm ER/K linker, mCerulean (FRET donor), and a Gα subunit. A (Gly-Ser-Gly)4 linker 
was inserted between all protein domains as part of the primer sequence to allow for free rotation between 
domains. Control GPCR sensors (–) did not contain a Gα subunit after mCerulean and instead had repeating 
(Gly-Ser-Gly)4 residues. All β2-AR-sensors also contained either an N-terminal HA-tag or a His-tag. All con-
structs were confirmed by sequencing. Peptide sequences for the 10, 20, and 30 nm ER/K linkers were described 
previously14. Briefly, the 10 nm ER/K linker is derived from Sus scrofa’s Myosin VI protein with the following 
amino acid sequence: EEEEKKKQQEEEAERLRRIQEEMEKERKRREEDEQRRRKEEEERRMKLEMEAKRK
QEEEERKKREDDEKRKKK. 30 nm linker is derived from the Kelch-motif family protein (Trichomonas vag-
inalis):EEEEKKKEEEEKKQKEEQERLAKEEAERKQKEEQERLAKEEAERKQKEEEERKQKEEEERKQ-
KEEEERKLKEEQERKAAEEKKAKEEAERKAKEEQERKAEEERKKKEEEERLERERKEREEQEKKAKEEAER-
IAKLEAEKKAEEERKAKEEEERKAKEEEERKKKEEQERLAKEKEEAERKAAEEKKAKEEQERKEKEEAERK. 
The 20 nm ER/K linker contains the first 130 residues from the 30 nm ER/K linker used in this study.
Mammalian cell preparation and sensor expression. HEK293T-Flp-In (HEK293T, Invitrogen) cells 
were cultured in DMEM supplemented with 10% FBS (v/v), 4.5 g L−1 D-glucose, 1% Glutamax, 20 mM HEPES, 
pH 7.5 at 37 °C in a humidified atmosphere at 5% CO2. HEK293T cells were plated into 6-wells tissue culture 
treated plates at ~30% confluence. Cells were transfected 16–20 h later with X-tremeGENE HP DNA transfec-
tion reagent. Transfection conditions including the amount of DNA (1.4–4 μg DNA + 4.2–6 μl reagent) and the 
length of transfection (control sensors: 18–24 h; Gα sensors: 22–32 h) were optimized to consistently yield equiv-
alent levels of sensor expression across different conditions. For GPCR-G protein competition assays, 100 ng, 
300 ng, or 1 μg of dark Gαx were co-transfected with 2 or 4 μg of indicated sensors. For all experiments sen-
sor integrity, localization, and sensor expression per optical density (O.D.) were tracked to ensure consistency. 
Experiments were conducted at 60–80% transfection efficiency evaluated by 20x and 40x magnification on a 
Nikon tissue-culture microscope enabled with fluorescence detection. Additionally, at the time of the experi-
ment, 60–90% of transfected cells expressed predominately plasma membrane localized sensor with minimal 
localization to the intracellular compartments. Each experiment was performed at equivalent sensor expression 
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and matched O.D. of the cell suspension using the following steps. First, cells were resuspended by gentle 
pipetting into their original media. Cells were then spun down (300 g, 3 min) and washed once with Buffer A. 
Subsequently, cells were resuspended in an appropriate volume of Buffer A to reach a 0.3 O.D. (A600 nm, BioMate 
3 S Spectrophotometer, Thermo Scientific, 3 mm path-length, optical glass cuvette) for all fluorescence-based 
measurements. Finally, sensor expression was measured by mCitrine fluorescence. mCitrine fluorescence was 
held within 1.6–2.4 × 106 counts-per-second (c.p.s) for a cell O.D. of 0.3. For each experiment, sensor integrity 
was tracked by measuring the mCitrine (excitation 490 bandpass 8 nm; emission range 500–600 bandpass 4 nm; 
emission maximum 525 nm) to mCerulean fluorescence ratio (excitation 430 bandpass 8 nm; emission range 
450–600 bandpass 4 nm; emission maximum 475 nm). As part of the sensor design, mCitrine and mCerulean 
label the C-terminus of GPCR and N-terminus of Gα subunit respectively. All experiments were conducted at 
mCitrine to mCerulean fluorescence ratio of 1.7–2.1.
Live cell microscopy and image analysis. HEK293T cells were plated (~15–20% confluence) on 
35 mm glass bottom dishes (MatTek Corp) coated with 10 μg mL−1 fibronectin. 14–16 h after plating (30–40% 
confluence), cells were transfected with Mirus-LT or XtremeGENE HP DNA transfection reagent. 16–22 h 
post-transfection cells were washed three times with Buffer A (37 °C) to remove excess phenol red from the 
media. Cells were subsequently imaged for no more than 30 min in Buffer A media. Cell images were collected 
at 60x magnification using a Nikon TiE microscope equipped with a mercury arc lamp, 60x and 100 × 1.4 
Numerical Aperture Plan-Apo oil objectives and with an Evolve 512 × 512 EM-Charge-Coupled-Device cam-
era (Photometrics). Z-stack images were taken with 1 μm steps and the resultant stack of images was decon-
volved using AutoQuantX software. Membrane expression in images was analyzed in ImageJ (NIH) using the 
threshold and measure tools to select and quantify membrane expression compared to internal localization. 
(Supplementary Fig. 1).
Fluorescence measurements. Using FluoroMax-4 fluorometer (Horiba Scientific), FRET spectra were 
generated by exciting cells at 430 nm (bandpass 8 nm) in an optical glass cuvette (3–3.30-SOG-3, Starna Cells 
Inc.). Emission was scanned from 450–600 nm (bandpass 4 nm). For mCitrine-only measurements, cells were 
exited at 490 nm (band pass 8 nm), and emission was recorded from 500–600 nm (bandpass 4 nm), emission 
maximum was set at 525 nm.
Live cell FRET calculations. FRET measurements were conducted at matched O.D. in Buffer A. 
Untransfected and transfected cells were resuspended in Buffer A at 0.3 O.D. To correct for scattering, FRET 
emission spectrum of an untransfected cell suspension, at equivalent O.D., was subtracted from FRET spectrum 
of the transfected cell suspension. The corrected FRET emission spectra were normalized to mCerulean emission 
(475 nm). FRET ratio was then calculated by dividing mCitrine emission (525 nm) by the mCerulean emission 
(475 nm).
ΔFRET experiments. Live cell ΔFRET experiments were conducted as previously described21. Briefly, cells 
were prepared and re-suspended into pre-warm Buffer A. 90 μL aliquots of cells were added into eppendorf tubes 
placed in a 37 °C water bath. Samples were treated with 10 μL of indicated ligand or buffer control for 1, 5, or 
10 min at 37°C. Separate and clean cuvettes were used to collect FRET spectra for treated and untreated samples 
to prevent cross-contamination. Change in FRET (ΔFRET) was calculated as FRETligand – FRETbuffer.
Reversibility of agonist-induced ΔFRET. Cells were prepared as described in the cell preparation sec-
tion. First, the untreated FRET ratio was measured. Untreated cells were spun down (600 g, 1 min), washed three 
times, and re-suspended into 400 μL of Buffer A. FRET spectra were serially collected for 90 μL aliquots. Next, a 
separate well was harvested into Buffer A supplemented with 100 μM isoproterenol. Cells were subsequently spun 
down (600 g, 1 min) and washed three times with 400 μL of Buffer A supplemented with 100 μM isoproterenol. 
The spin and wash steps were completed within 5 minutes. ΔFRET was calculated by subtracting the untreated 
FRET ratios from the FRET ratios measured in the isoproterenol treated conditions. To assess reversibility of 
the isoproterenol induced ΔFRET response, cells were incubated in Buffer A supplemented with 100 μM iso-
proterenol for 3 minutes in a 37°C water bath. Cells were spun down (600 g, 1 min) and washed three times, and 
re-suspended into 400 μL of Buffer A. FRET spectra were serially collected for 90 μL aliquots. ΔFRET was cal-
culated by subtracting the untreated FRET ratios from the FRET ratios measured in the isoproterenol wash out 
conditions. mCitrine:O.D. ratio was kept consistent across all conditions to ensure that each FRET measurement 
was taken at consistent sensor expression levels at a fixed density of cells.
Membrane preparation. 24 or 48 h post transfection (XtremeGene HP) HEK293T cells expressing indi-
cated sensors were collected and washed once with cold PBS buffer containing 1.5 μg mL−1 aprotinin and 1.5 μg 
mL−1 leupeptin. Where appropriate, steps were carried out on ice and/or at 4 °C. Cells were incubated in hypo-
tonic lysis buffer (20 mM HEPES, 0.5 mM EDTA, 0.1 mM DTT, 1.5 μg mL−1 aprotinin, 1.5 μg mL−1 leupeptin 
and 50 μg mL−1 phenylmethanesulfonyl fluoride, pH 7.4) for 5 min. Cells were lysed with a 1 mL syringe in a 
pre-chilled cell homogenizer (Isobiotec) using an 8-micron clearance. Lysed cells were spun at 500 g for 5 min at 
4 °C. Supernatants containing cell membranes were spun at 45,000 rpm in an ultracentrifuge for 45 min at 4 °C. 
Membrane pellets were washed 3x with pre-chilled suspension buffer containing 20 mM HEPES, 0.5 mM EDTA, 
5 mM MgCl2, 0.1 mM DTT, 3 μM GDP, 1.5 μg mL−1 aprotinin, 1.5 μg mL−1 leupeptin and 50 μg mL−1 phenylmeth-
anesulfonyl fluoride at pH 7.4. For radioligand binding assays, membranes were washed 3x with cold resuspen-
sion buffer supplemented with 100 mM NaCl. Membranes were resuspended in 1 mL of indicated pre-chilled 
buffer using a rotary pestle (Fisherbrand, 30 s). Membranes were spun again at 45,000 rpm for 45 min at 4 °C. 
Membrane pellets were resuspended in their respective resuspension buffers using a dounce homogenizer. Total 
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protein concentration (mg mL−1) was calculated using a DC Protein Assay (Bio-Rad). Membranes were flash 
frozen in liquid nitrogen and stored at −80 °C.
Sensor purification from HEK293 cells. For anti-Gβ experiments, purification of His tag-β2-AR-G pro-
tein and control (−) sensors from HEK293T cells followed the previously published protocol16. Frozen mem-
branes were thawed quickly to room temperature and briefly re-homogenized with a rotary pestle. 5% cholate 
buffer (5% sodium cholate in 50 mM HEPES, 3 mM MgCl2, 50 mM NaCl with 1 μg mL−1 aprotinin, 1 μg mL−1 leu-
peptin, 10 μg mL−1 phenylmethanesulfonyl fluoride, and 5.5 mM β-mercaptoethanol, pH 8.0) was added to a final 
concentration of 1% cholate. This mixture was incubated on ice for 45 min and separated by ultracentrifugation at 
~105,000 g for 40 min at 4 °C. The supernatant was harvested and diluted drop wise with four volumes of Buffer C 
to one volume of supernatant, and was pipetted gently to mix. The diluted supernatant was added to nickel-NTA 
resin (Qiagen) and incubated 30 min at 4 °C with rotation. The resin was washed 3x with 500 μL Buffer C + 5 mM 
imidazole. The final wash was removed and the resin was brought to room temperature and eluted for 3–5 min 
with 150 μL of elution buffer (Buffer C + 200 mM imidazole). The eluted resin was spun down, the superna-
tant harvested, and measured for mCerulean and mCitrine fluorescence in a fluorometer (as described above). 
Samples were stored in SDS laemmli sample buffer at −80 °C.
Western blot. For anti-HA western blot, 20 μg of membranes containing β2-AR-Gs sensor were boiled in 
Buffer B supplemented with Glycoprotein Denaturing Buffer (NEB) at 95 °C for 5 min. Boiled samples were sub-
sequently treated with 500 units of PNGase F (NEB) for three hours at 37 °C. For anti-Gβ, equivalent amount 
of sensors, as measured by mCitrine fluorescence, were loaded on SDS-PAGE Gels (10% polyacrylamide). Gels 
were imaged for mCitrine fluorescence (excitation 488 nm, emission 520 nm, bandpass 40 nm) using a Typhoon 
Gel Imager (GE Healthcare). Gels were transferred to PVDF membranes for three hours at 300 mA. Anti-HA and 
anti-Gβ were blocked with 2% milk/TRIS-buffered saline with 1% Tween (TBST) for either one hour at room 
temperature or 4 °C overnight. Blots were then incubated with indicated primary antibody at a 1:1,000 dilution in 
5% milk/TBST. For the anti-Gβ experiment, blots were washed with TBST, and incubated with 1:5,000 or 1:10,000 
horseradish peroxidase (HRP) conjugated goat anti-rabbit IgG secondary antibody (0031460, Fisher Scientific) 
in 5% milk/TBST or 5% BSA/TBST for one hour at room temperature. Similarly for anti-HA experiments, blots 
were incubated with 1:10,000 Sheep anti-mouse HRP conjugated secondary antibody (GE Healthcare, NA931). 
All blots were developed with Immobilon Western Chemiluminescent HRP Substrate (Millipore). Blots were 
imaged using a ChemiDoc-It Imaging system (UVP). Images of gels and blots were prepared using ImageJ (NIH).
Radio-ligand assays. Radio-ligand assays followed the previously published protocol39. Bmax values 
were estimated by incubation of 2.5, 5, and 10 μg of membrane with 5 nM [3H]-dihydroalprenolol ([3H]-DHA; 
PerkinElmer) for 90 min at room temperature in Tris-Buffered-Saline (TBS) pH 7.4. Samples were transferred to 
GF/C membranes pre-treated with 0.3% PEI solution in TBS, washed extensively with cold TBS, and dried over 
night at room temperature. Following addition of scintillation liquid (Microscint0, PerkinElmer,) radioactiv-
ity was measured using a 96-well scintillation counter (TopCount, PerkinElmer. Non-specific binding was esti-
mated with 10 μM propranolol treatment and was < 1% of total binding. Dissociation constant (Kd) of [3H]-DHA 
binding was determined by incubation of 7–10 pM (7–10 fmol/ml) of receptor with increasing concentrations of 
[3H]-DHA. KD of [3H]-DHA binding was ~0.2 nM for β2-AR-Gs and control sensors. Competitive inhibition (Ki) 
was assessed by incubation of 7 pM of receptor with increasing concentrations of isoproterenol (ISO) or buffer 
blank in the presence of 2 nM [3H]-DHA, for 90 min at room temperature. Radioactivity in samples for KD and Ki 
experiments was measured as described above. Non-specific binding in all instances was found to be < 1%. Each 
experiment was done at least twice with different membrane preparations, with three separate samples prepared 
per condition, per experiment.
cAMP assays. 28–32 h post transfection (XtremeGENE HP) HEK293T cells expressing indicated sensor were 
harvested to assess cAMP levels using the bioluminescent cAMP Glo assay (Promega). Cells were gently sus-
pended in their original media, were counted using a hemocytometer, and spun down (300 g, 3 min). Appropriate 
volume of Buffer D was added to reach 2 × 106 cells mL−1 density for basal experiments or 4 × 106 cells mL−1 den-
sity for ligand based assays. Cell suspensions were aliquoted into 96 wells round-bottom opaque plates. To assess 
basal cAMP production, cells were incubated in Buffer D supplemented with 0.25 mM IBMX for 15 min at 37 °C. 
To test isoproterenol-induced changes in cAMP levels, cells were incubated with varying concentration of isopro-
terenol for 3 min at room temperature. To assess Emax for cAMP production, cells were incubated with 100 μM of 
isoproterenol and 100 μM of forskolin for 3 min at room temperature or 37 °C. For cAMP suppression assays, cells 
were treated with 1 μM forskolin and with or without ligand for 15 min at 37 °C. Subsequently, cells were lysed 
and the protocol was followed according to the manufacturer’s recommendation (Promega). Luminescence was 
measured using a microplate luminometer reader (SpectraMax M5e, Molecular Devices). cAMP levels (relative 
luminescence unit, RLU) were evaluated by subtracting the untransfected background from the transfected con-
ditions. Each experiment had four technical repeats per condition and was independently repeated at least three 
times (N > 3).
IP1 assays. 28–32 h post transfection (XtremeGENE HP) HEK293T cells expressing the indicated sensor 
were harvested to assess IP1 levels using the IP-One HTRF assay kit (Cisbio). Cells were gently suspended in 
their original media, counted using a hemocytometer, and spun down (300 g, 3 min). An appropriate volume of 
StimB buffer (CisBio: 10 mM Hepes, 1 mM CaCl2, 0.5 mM MgCl2, 4.2 mM KCl, 146 mM NaCl, 5.5 mM glucose, 
50 mM LiCl, pH 7.4) was added to reach 3 × 106 cells mL−1 density. Cells were incubated at 37 °C for 15 min. The 
manufacturer’s protocol was modified in order to achieve a high signal to noise ratio. 150 μL of suspension was 
incubated for one hour with 30 μL of lysis buffer (Cisbio), 54 μL StimB buffer, 6 μL IP1 conjugated to d2 dye, and 
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6 μL terbium cryptate-labeled anti-IP1 monoclonal antibody. IP1 FRET spectra were collected by exciting samples 
at 340 nm (bandpass 15 nm). Emission counts were recorded from 600–700 nm (bandpass 10 nm) using a long 
pass 475 nm filter (FSQ GG475, Newport). Raw IP1 signal was calculated from the 665 nm to 620 nm ratio. Basal 
IP1 signal was corrected by subtracting the untransfected IP1 ratio from cells expressing transfected sensor. For 
ligand experiments, data are presented as a change in raw IP1 ratio following drug treatment. Each experiment 
had four repeats per condition and was independently repeated at least three times (N > 3).
Analysis of concentration-response curves and radio-ligand assays. Data were analyzed in 
GraphPad Prism 7.0c (Graphpad Software, Inc.) to obtain EC50 values for the ΔFRET and cAMP accumulation 
assays, and IC50, Ki, KD values for radio-ligand binding assays. Sigmoidal curves from ΔFRET and cAMP exper-
iments were analyzed using non-linear regression curve fitting using log (agonist or inhibitor) versus response 
(three parameters). The equilibrium dissociation constant for isoproterenol binding to β2-AR-Gs sensors (Ki) and 
IC50 were calculated by fitting radio-ligand binding curve using non-linear regression analysis with competitive 
one site – fit Ki or competitive one site fit logIC5O parameters respectively. Ligand efficacy (τ) was evaluated using 
the operational model of agonism as described previously. Briefly, dose response curves were fitted to the opera-
tional model of agonism using the following equation:
=
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where Emax is the maximal cAMP response of the system assessed by treating the cells with 100 μM forskolin 
and 100 μM isoproterenol, E is the cAMP response to varying concentration of isoproterenol ([A]), and n is the 
slope of the transducer function that links ligand occupancy to response. KA value was constrained to the respec-
tive Ki values derived from competitive radio-ligand binding assay (see above). 1/τ values were calculated to 
assess the fraction of isoproterenol-bound β2-AR-Gs fusion, which generates the half maximal cAMP response 
(see Supplementary Table 5).
Statistical Analysis. Data are expressed as mean values ± S.E.M. Experiments were independently con-
ducted at least three times, with 3–6 technical repeats per condition (N > 3). Statistical analysis was performed 
using GraphPad Prism 7.0c (Graphpad Software, Inc.) Statistical significance was performed for individual 
experiments using paired Student’s t-test. To assess how the data varied across experimental repeats, data were 
pooled and paired or unpaired Student’s t-tests were conducted to evaluate significance. One-way ANOVA with a 
Tukey’s post-test was performed to assess significance when evaluating comparisons between multiple conditions 
(Fig. 3d,e,g) or across fusions (Figs 5–6) with p-values *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001.
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